Quantitative analysis of the Enhanced Permeation and Retention (EPR) effect

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Wong, Andrew D ^a   Ye, Mao ^b   Ulmschneider, Martin B ^a   Searson, Peter C ^a,b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MACROGOL DERIVATIVE;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RETENTION; DRUG TRANSPORT; DRUG UPTAKE; ENHANCED PERMEATION AND RETENTION EFFECT; HUMAN; MATHEMATICAL MODEL; PHARMACOLOGICAL PARAMETERS; QUANTITATIVE ANALYSIS; TUMOR MICROENVIRONMENT; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; NEOPLASM; PERMEABILITY; THEORETICAL MODEL;

ANIMALIA;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, THEORETICAL; NEOPLASMS; PERMEABILITY; POLYETHYLENE GLYCOLS; TUMOR MICROENVIRONMENT;

EID: 84929121287     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123461     Document Type: Article

References (29)

1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583-92. doi: 10.1038/nrc1893 PMID: 16862189.
2. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced drug delivery reviews. 2011; 63(3):136-51. doi: 10.1016/j.addr.2010.04.009 PMID: 20441782.
3. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. Journal of controlled release: official journal of the Controlled Release Society. 2012; 164(2):138-44. doi: 10.1016/j.jconrel.2012.04.038 PMID: 22595146.
4. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. P Natl Acad Sci USA. 1998; 95 (8):4607-12. doi: 10.1073/Pnas.95.8.4607 PubMed WOS:000073120800097. PMID: 9539785
5. Jain RK. Determinants of Tumor Blood-Flow - A Review. Cancer research. 1988; 48(10):2641-58. PubMed ISI:A1988N269700003. PMID: 3282647
6. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995; 55(17):3752-6. Epub 1995/09/01. PMID: 7641188.
7. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007; 2(12):751-60. doi: 10.1038/Nnano.2007.387 PubMed ISI:000251456500010. PMID: 18654426
8. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012; 338(6109):903-10. doi: 10.1126/science.1226338 PMID: 23161990; PubMed Central PMCID: PMC3660151.
9. Gibaldi M, Perrier D. Pharmacokinetics. 3rd ed. 978-0824702953 I-, editor. New York: Dekker; 2006.
10. Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. Journal of controlled release: official journal of the Controlled Release Society. 2014; 187:133-44. doi: 10.1016/j.jconrel.2014.05.036 PMID: 24874289.
11. Barenholz Y. Doxil(R) - the first FDA-approved nano-drug: lessons learned. Journal of controlled release: official journal of the Controlled Release Society. 2012; 160(2):117-34. doi: 10.1016/j.jconrel.2012.03.020 PMID: 22484195.
12. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994; 54(4):987-92. PMID: 8313389.
13. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clinical pharmacokinetics. 2003; 42(5):419-36. doi: 10.2165/00003088-200342050-00002 PMID: 12739982.
14. Cameron JR, Skofronick JG, Grant RM, Cameron JR. Physics of the body. 2nd ed. Madison, Wis.: Medical Physics Pub.; 1999. xv, 394 p. p.
15. Dawidczyk CM, Russell LM, Searson PC. Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Frontiers in chemistry. 2014; 2:69. Epub 2014/09/10. doi: 10.3389/fchem.2014.00069 PMID: 25202689; PubMed Central PMCID: PMC4142601.
16. Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, Yang HS, et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clinical Cancer Research. 2006; 12(10):3193-9. doi: 10.1158/1078-0432.Ccr-05-2365 PubMed WOS:000237685800034. PMID: 16707620
17. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clinical pharmacology and therapeutics. 1993; 53 (5):555-61. PMID: 8387903.
18. Jacquet JM, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, et al. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer chemotherapy and pharmacology. 1990; 27(3):219-25. PMID: 2265458.
19. Erttmann R, Erb N, Steinhoff A, Landbeck G. Pharmacokinetics of doxorubicin in man: dose and schedule dependence. Journal of cancer research and clinical oncology. 1988; 114(5):509-13. PMID: 3182911.
20. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. Journal of pharmaceutical sciences. 2002; 91(6):1488-501. doi: 10.1002/jps.10161 PMID: 12115848.
21. Hilmas DE, Gillette EL. Morphometric analyses of the microvasculature of tumors during growth and after x-irradiation. Cancer. 1974; 33(1):103-10. Epub 1974/01/01. PMID: 4810083.
22. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7(2):243-54. Epub 2001/03/10. PMID: 11234875.
23. Laginha KM, Verwoert S, Charrois GJ, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(19 Pt 1):6944-9. Epub 2005/10/06. doi: 10.1158/1078-0432.CCR-05-0343 PMID: 16203786.
24. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. Journal of clinical pharmacology. 1996; 36 (1):55-63. Epub 1996/01/01. PMID: 8932544.
25. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer research. 1994; 54(13):3352-6. Epub 1994/07/01. PMID: 8012948.
26. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Abra RM, Uster PS, Peters AM, et al. Influence of tumour size on uptake of(111)ln-DTPA-labelled pegylated liposomes in a human tumour xenograft model. British journal of cancer. 2000; 83(5):684-8. Epub 2000/08/17. doi: 10.1054/bjoc.2000.1320 PMID: 10944612; PubMed Central PMCID: PMC2363509.
27. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17(11):3512-21. Epub 1999/11/05. PMID: 10550149.
28. Stapleton S, Milosevic M, Allen C, Zheng J, Dunne M, Yeung I, et al. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PloS one. 2013; 8(12): e81157. Epub 2013/12/07. doi: 10.1371/journal.pone.0081157 PMID: 24312530; PubMed Central PMCID: PMC3846845.
29. Folarin AA, Konerding MA, Timonen J, Nagl S, Pedley RB. Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography. Microvascular research. 2010; 80(1):89-98. Epub 2010/03/23. doi: 10.1016/j.mvr.2010.03.007 PMID: 20303995.